Recursion Pharmaceuticals (RXRX) executive compensation, 2026 proxy

Christopher Gibson, former Chief Executive Officer and President and current Chair of the Board, was paid $9.6M in fiscal 2025, up 13% from $8.5M the year before. The CEO-to-median-employee pay ratio was 33:1, on median employee pay of $287,986.

Filed
April 30, 2026
Annual meeting
June 17, 2026
Pay year
fiscal 2025
Named executives
3
CEO total pay
$9.6M+13% vs prior year
CEO to median employee
33:1median $287,986
CEO pay in equity
90%$8.7M in awards
Prior say-on-pay support
98%of votes cast
CEO Total Compensation
$9,607,508For fiscal 2025
CEO Pay Ratio
33:1Compared to median employee
Median Employee Pay
$287,986Annual total compensation
Say-on-Pay Support
98%At prior annual meeting

How Gibson was paid

$9.6M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary7%Stock awards40%Option awards50%Non-equity incentive3%All other compensation0%

Named executive officers

ExecutiveTotal
Christopher Gibsonformer Chief Executive Officer and President and current Chair of the Board$9,607,508
Najat Khancurrent Chief Executive Officer and President$5,349,065
Ben TaylorChief Financial Officer$1,328,483

What changed and why

  • $9.6MChristopher Gibson received total compensation of $9,607,508 in fiscal year 2025.
  • Najat Khan was appointed as Chief Executive Officer and President effective January 1, 2026.
  • 80%Short-term incentive compensation plans paid out at 80% of target in 2025.
  • Equity awards beginning in fiscal year 2026 will be granted solely in RSUs.
  • 98%Stockholders approved the prior year say-on-pay proposal with approximately 98% support.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.